Actos Bladder Cancer Lawsuit
Centralized Actos® litigation

The U.S. District Panel on Multidistrict litigation is scheduled for an oral hearing on December 1, 2011 to discuss whether Actos lawsuits should be centralized before one judge for pretrial proceedings. Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients diagnosed with type II diabetes. Since its release, Actos became Takeda Pharmaceuticals best-selling drug with record sales of $4.3 billion in 2010. However, a number of reported bladder cancer cases began to surface, causing the Food and Drug Administration (FDA) to get involved in 2010. Accusations were made against Takeda Pharmaceuticals, Japan’s largest drug maker, stating that taking the popular Actos drug causes bladder cancer when taken for long periods of time, 12 months or more. In September of 2010, FDA officials released information regarding an on-going ten year study of Actos linking the drug to bladder cancer when taken for long periods of time. By August of 2011, new warning labels for Actos were approved by the FDA. These new warning labels include the dangers associated with taking Actos for 12 months or more. The link between Actos and bladder cancer caused sales for Takeda Pharmaceuticals to drop in recent months. Prior to September of 2011, sales were reportedly $1.75 billion. The drug company also estimates that 31% of its profits will drop by March of 2012. Currently, Takeda Pharmaceuticals is aware of 54 cases in the United States which all claim that Actos causes bladder cancer; however that number is expected to rise as more victims come forth in complaints against the company. The U.S. District Panel on Multidistrict Litigation will discuss next month whether Actos lawsuits should be consolidated into one class action lawsuit.


About the Contributor

Related Posts